Dr. Agrawals Eye Hospital Intrinsic Value
Dr. Agrawals Eye Hospital intrinsic value. Dr. Agrawals Eye Hospital (DRAGARWQ) median intrinsic value is ₹1905.60 from 10 valuation models (range ₹1043–₹3939), vs current price ₹5215.00 — -63.5% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with DRAGARWQ fair price to assess whether the stock is under or overvalued.
DRAGARWQ Valuation Methods Summary — DCF, Graham Number & P/E
Dr. Agrawals Eye Hospital intrinsic value across 10 models vs current price ₹5215.00 — upside/downside and value range per method. Read DRAGARWQ dividend growth for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1905.60 | ₹1524.48 - ₹2286.72 | -63.5% | EPS: ₹158.80, Sector P/E: 12x |
| Book Value Method | asset | ₹1043.00 | ₹938.70 - ₹1147.30 | -80.0% | Book Value/Share: ₹692.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1564.50 | ₹1408.05 - ₹1720.95 | -70.0% | Revenue/Share: ₹1008.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹2086.00 | ₹1877.40 - ₹2294.60 | -60.0% | EBITDA: ₹158.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹3939.17 | ₹3151.34 - ₹4727.00 | -24.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2444.39 | ₹2199.95 - ₹2688.83 | -53.1% | EPS Growth: 19.2%, Fair P/E: 15.4x |
| Growth Adjusted P/E | growth | ₹1564.50 | ₹1408.05 - ₹1720.95 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 8.6x |
| ROE Based Valuation | profitability | ₹2607.50 | ₹2346.75 - ₹2868.25 | -50.0% | ROE: 22.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1564.50 | ₹1408.05 - ₹1720.95 | -70.0% | EPS: ₹158.80, BVPS: ₹692.00 |
| Dividend Yield Method | dividend | ₹1564.50 | ₹1408.05 - ₹1720.95 | -70.0% | DPS: ₹7.00, Target Yield: 3.5% |
DRAGARWQ Intrinsic Value vs Market Price — All Valuation Models
Dr. Agrawals Eye Hospital fair value range ₹1043–₹3939 vs current market price ₹5215.00 across 10 valuation models. For current market price and key ratios, visit DRAGARWQ share price screener.
DRAGARWQ Intrinsic Value Analysis — Undervalued or Overvalued?
Dr. Agrawals Eye Hospital median intrinsic value ₹1905.60, current price ₹5215.00 — Trading Above Calculated Value by 63.5%, margin of safety -100.0%.
What is the intrinsic value of DRAGARWQ?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Dr. Agrawals Eye Hospital (DRAGARWQ) is ₹1905.60 (median value). With the current market price of ₹5215.00, this represents a -63.5% variance from our estimated fair value.
The valuation range spans from ₹1043.00 to ₹3939.17, indicating ₹1043.00 - ₹3939.17.
Is DRAGARWQ undervalued or overvalued?
Based on our multi-method analysis, Dr. Agrawals Eye Hospital (DRAGARWQ) appears to be trading above calculated value by approximately 63.5%.
DRAGARWQ Financial Health — Key Ratios vs Industry Benchmarks
Dr. Agrawals Eye Hospital financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.44 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 22.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.66x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
DRAGARWQ Cash Flow Quality — Operating & Free Cash Flow
Dr. Agrawals Eye Hospital operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹145 Cr | ₹58 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹94 Cr | ₹28 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹90 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹70 Cr | ₹35 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹57 Cr | ₹34 Cr | Positive Free Cash Flow | 8/10 |